STAAR Surgical Company (NASDAQ:STAA) Files An 8-K Regulation FD Disclosure
Representatives of STAAR Surgical Company will give presentations to investors commencing on January 7, 2019. A copy of the slide presentation they will use in their presentations is furnished as Exhibit 99.1 to this Report and is incorporated herein by this reference.
The information furnished herewith to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.
|Item 9.01||Financial Statements and Exhibits|
|99.1||Slide Presentation dated January 7, 2019.|
STAAR SURGICAL CO Exhibit
EX-99.1 2 tv510384_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 STAAR Surgical Company NASDAQ: STAA Investor Presentation | January 7,…
To view the full exhibit click
About STAAR Surgical Company (NASDAQ:STAA)
STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses (IOLs) used in cataract surgery and implantable collamer lenses (ICLs) used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). It sells its products in approximately 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.